HOME >> MEDICINE >> NEWS
New 'litmus test' could aid discovery of anti-cancer drugs

EVANSTON, Ill. --- Using the unusual color properties of gold at the nanoscale, scientists at Northwestern University have developed a "litmus test" for DNA and small molecule binding that eventually could be used by pharmaceutical companies to rapidly identify promising candidates for new anti-cancer drugs.

The detection system, called colorimetric screening, can be used to detect a variety of targets, such as DNA, small molecules and proteins, that bind to DNA, and the strength of the bond is indicated by a simple color change.

In a paper reported online today (March 28) by the Journal of the American Chemical Society (JACS), the research team used the colorimetric method to screen for molecules that can facilitate the formation of a special form of DNA called a triple helix. Triple helix DNA involves three strands rather than the two associated with normal DNA. However, unlike double helix DNA, the triple helix is unstable alone and requires a small molecule triplex binder to increase its stability. This research builds on work reported March 6 in the German journal Angewandte Chemie in which the same method was used to screen small molecules for their binding affinity to duplex DNA.

"Pharmaceutical companies are targeting DNA for different therapies, and they need to identify DNA or small molecules that selectively bind to DNA to turn on or off the gene expression related to a particular disease," said Chad A. Mirkin, George B. Rathmann Professor of Chemistry, professor of medicine and professor of materials science and engineering, who led both studies. "Our method, which is simpler, faster and more convenient than conventional methods, should help researchers zero in on potential anti-cancer agents from their large libraries of candidates more quickly."

In the JACS paper, the researchers demonstrated that when a triplex binder binds to a given DNA triple helix in solution the strength of that binding event can be detected by
'"/>

Contact: Megan Fellman
fellman@northwestern.edu
847-491-3115
Northwestern University
28-Mar-2006


Page: 1 2 3

Related medicine news :

1. Seat belt injuries could signal more serious trauma in children
2. Using MRI for diagnosis could help prevent breast cancer progression
3. Metabolic study in mice could lead to good cholesterol boosters
4. Miniature implanted devices could treat epilepsy, glaucoma
5. Health reform bills could improve quality and efficiency, but fall short of national plan
6. Experts predict Tamiflu could halve the pandemic influenza death toll versus no intervention
7. Split the difference: Pill-splitting study looks at cost-saving step that could be used by millions
8. Oxygen trick could see organic costs tumble
9. New study could bring relief to sweltering city slickers
10. Decision aid tool could cut the number of Caesarean sections by 4000 a year
11. Papillomavirus vaccine could substantially reduce cervical cancer incidence

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New litmus test could aid discovery anti cancer drugs

(Date:10/20/2014)... York, NY (PRWEB) October 20, 2014 ... based non-profit organization that helps New Yorkers living ... positive changes toward health, housing, recovery and self-sufficiency. ... have transformed the local community through their tireless ... Director, Marc Shapses , has been selected ...
(Date:10/20/2014)... Ga. (PRWEB) October 20, 2014 ... and relationship-marketing firm, announced today that William H. ... named the 2014 ISE® Luminary Leadership Award winner. ... the achievements of an outstanding leader and industry ... and contributions in advancing the information security industry. ...
(Date:10/20/2014)... D.C. (PRWEB) October 20, 2014 Zereana Jess-Huff, ... crowned Mrs. Maryland 2014 on a platform to think outside ... scars, and uses her position to raise awareness about women’s ... awareness for breast cancer. You say the color pink and ... I know for a fact that it has not been ...
(Date:10/20/2014)... My Clients Plus ( http://www.MyClientsPlus.com ) ... The new module enables easy administration and routing of ... care. , This application allows users such as Therapists ... a to-do item to a specific client, categorize tasks ... reoccurring reminders for follow-ups. It's designed to enable ...
(Date:10/20/2014)... AttorneyOne.com, a recognized authority on law, update the ... on Sit and Slim II . , The ... use Sit and Slim II because it contains Sibutramine ... weight loss product on various websites and possibly in some ... for safety reasons, can significantly increase blood pressure and/or pulse ...
Breaking Medicine News(10 mins):Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:My Clients Plus Announces New Workflow Management Software 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2
(Date:10/20/2014)... de octubre de 2014  PneumRx, Inc. ( ... la pulmonología intervencional, anunció hoy la conclusión de ... meses antes de lo programado. El Estudio Clínico RENEW ... de investigación (IDE) aprobada por la FDA (Administración ... espiral de reducción de volumen pulmonar PneumRx RePneu, ...
(Date:10/20/2014)... , Oct. 20, 2014  ResMed (NYSE: ... the ResMed Data Exchange program, a comprehensive suite ... equipment (HME) and other health care providers. ... access to critical patient information. It integrates valuable ... and U-Sleep™ patient management platforms with customers, in-house ...
(Date:10/20/2014)... 20, 2014  AnaptysBio, Inc., a leader in ... announced the appointment of Marco Londei , ... lead the preclinical and clinical development of AnaptysBio,s ... pleased to welcome Dr. Londei to AnaptysBio,s executive ... and Chief Executive Officer of AnaptysBio. "Dr. Londei,s ...
Breaking Medicine Technology:PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3ResMed Launches ResMed Data Exchange 2AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2
Cached News: